FINWIRES · TerminalLIVE
FINWIRES

TPE:6472

4 stories mentioning TPE:6472Updated 29d ago

Every FINWIRES story that references TPE:6472, newest first.

Asia

Bora Pharma Refutes Report Projecting $2.5 Billion Value for Insilico Alliance

Bora Pharmaceuticals (TPE:6472) denied a media report valuing its strategic alliance with AI drug discovery firm Insilico Medicine at more than $2.5 billion, according to a Wednesday Taiwan Exchange filing.The pharmaceutical company said the Commercial Times report does not represent company-issued financial projections.Bora said it does not release financial forecasts or business projections and advised investors to refer to its filings on Taiwan's Market Observation Post System for official financial and business information.

TPE:6472
Asia

Insilico Medicine, Bora Pharmaceuticals Form AI Drug Discovery Alliance

Insilico Medicine (HKG:3696) said it entered into a strategic alliance with Bora Pharmaceuticals (TPE:6472) to collaborate on AI-driven drug discovery and development under a framework that could be valued at over $2.5 billion if fully implemented.The proposed collaboration, subject to the execution of definitive agreements, will combine Insilico's Pharma.AI platform for target discovery, generative chemistry and molecule optimization with Bora's drug development, manufacturing, quality and commercialization capabilities.The alliance aims to integrate AI-enabled drug discovery with development and manufacturing to accelerate the delivery of medicines for patients with unmet medical needs, according to a Wednesday news release.

HKG:3696TPE:6472
Research

SinoPac Upgrades Bora Pharmaceuticals to Buy from Neutral; Price Target is NT$537

Bora Pharmaceuticals (TPE:6472) has an average rating of overweight and mean price target of NT$496.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

TPE:6472
Research

Fubon Securities Upgrades Bora Pharmaceuticals to Buy from Neutral; Price Target is NT$520

Bora Pharmaceuticals (TPE:6472) has an average rating of overweight and mean price target of NT$477.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

TPE:6472

Track with the FINWIRES app suite

FolioX
FolioX
Track TPE:6472 in your portfolio
WheelAI
WheelAI
Analyze TPE:6472 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TPE:6472